VIRAL HEPATITIS Cost-effectiveness of direct-acting antivirals for chronic hepatitis C

被引：3
|
作者：
Sroczynski, Gaby [1 ]
Siebert, Uwe [1 ]
机构：
[1] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth & Hlth Technol Assessment, A-6060 Hall In Tirol, Austria
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2013年 / 10卷 / 10期
关键词：
THERAPY; HEALTH;
D O I：
10.1038/nrgastro.2013.162
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
A new study has reported the long-term effectiveness and cost-effectiveness of the direct-acting antivirals telaprevir and boceprevir for the treatment of Chronic hepatitis C. These findings have the potential to be used to guide clinical and reimbursement decisions for treating populations with a high prevalence of HCV infection.
引用
收藏
页码：572 / 574
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of direct-acting antivirals for chronic hepatitis C
    Gaby Sroczynski
    Uwe Siebert
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 : 572 - 574
  • [2] Direct-acting antivirals for hepatitis C treatment: effectiveness versus cost-effectiveness
    Chhatwal, Jagpreet
    FUTURE VIROLOGY, 2015, 10 (08) : 929 - 932
  • [3] Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
    Chen, Pingyu
    Jin, Min
    Cao, Yang
    Li, Hongchao
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (03) : 371 - 387
  • [4] Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis
    Ciaccio, Antonio
    Cortesi, Paolo A.
    Bellelli, Giuseppe
    Rota, Matteo
    Conti, Sara
    Okolicsanyi, Stefano
    Rota, Monica
    Cesana, Giancarlo
    Mantovani, Lorenzo G.
    Annoni, Giorgio
    Strazzabosco, Mario
    LIVER INTERNATIONAL, 2017, 37 (07) : 982 - 994
  • [5] Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia
    Walker, Josephine G.
    Mafirakureva, Nyashadzaishe
    Iwamoto, Momoko
    Campbell, Linda
    San Kim, Chamroeun
    Hastings, Reuben A.
    Doussett, Jean-Philippe
    Le Paih, Mickael
    Balkan, Suna
    Marquardt, Tonia
    Maman, David
    Loarec, Anne
    Coast, Joanna
    Vickerman, Peter
    LIVER INTERNATIONAL, 2020, 40 (10) : 2356 - 2366
  • [6] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA
    Ignatyeva, V
    Pyadushkina, E.
    Derkach, E., V
    VALUE IN HEALTH, 2019, 22 : S646 - S647
  • [7] Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C
    Pingyu Chen
    Min Jin
    Yang Cao
    Hongchao Li
    Applied Health Economics and Health Policy, 2021, 19 : 371 - 387
  • [8] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR CHRONIC HEPATITIS C TREATMENT-NAIVE PATIENTS IN CHINA
    Wei, X.
    Feng, Y.
    Yang, L.
    VALUE IN HEALTH, 2019, 22 : S197 - S198
  • [9] Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong
    Lo, Angeline Oi-Shan
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (05) : 1071 - 1078
  • [10] Cost-effectiveness of Treating Acute versus Chronic Hepatitis C Infection Using Direct-Acting Antivirals
    Bethea, Emily D.
    Chen, Qiushi
    Hur, Chin
    Chung, Raymond T.
    Chhatwal, Jagpreet
    HEPATOLOGY, 2017, 66 : 10A - 10A
12345